HC Wainwright Reiterates Buy Rating for Zenas BioPharma (NASDAQ:ZBIO)

Zenas BioPharma (NASDAQ:ZBIO)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They presently have a $44.00 price target on the stock. HC Wainwright’s price objective would suggest a potential upside of 91.06% from the company’s previous close.

A number of other brokerages have also recently issued reports on ZBIO. Wedbush reissued an “outperform” rating and issued a $45.00 target price on shares of Zenas BioPharma in a research report on Monday, December 22nd. Morgan Stanley lifted their price target on Zenas BioPharma from $19.00 to $21.00 and gave the stock an “equal weight” rating in a research report on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Zenas BioPharma in a research note on Monday, December 29th. Jefferies Financial Group reissued a “buy” rating and issued a $48.00 price objective on shares of Zenas BioPharma in a report on Tuesday, January 6th. Finally, Evercore started coverage on shares of Zenas BioPharma in a research report on Wednesday, November 26th. They set an “outperform” rating and a $55.00 target price on the stock. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Zenas BioPharma has an average rating of “Moderate Buy” and an average price target of $44.14.

Zenas BioPharma Price Performance

Shares of NASDAQ ZBIO opened at $23.03 on Tuesday. The company has a debt-to-equity ratio of 0.32, a current ratio of 5.61 and a quick ratio of 5.66. The company has a market cap of $1.32 billion, a price-to-earnings ratio of -2.95 and a beta of -1.94. The stock’s 50-day moving average is $22.91 and its two-hundred day moving average is $27.15. Zenas BioPharma has a 1-year low of $6.11 and a 1-year high of $44.60.

Zenas BioPharma (NASDAQ:ZBIO) last released its quarterly earnings data on Monday, March 16th. The company reported ($4.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.22) by ($3.32).

Insider Buying and Selling

In other news, CEO Leon O. Moulder, Jr. purchased 57,000 shares of the company’s stock in a transaction dated Monday, February 2nd. The stock was acquired at an average price of $17.96 per share, for a total transaction of $1,023,720.00. Following the completion of the transaction, the chief executive officer directly owned 423,155 shares in the company, valued at $7,599,863.80. This represents a 15.57% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, Director Patricia L. Allen bought 15,700 shares of the company’s stock in a transaction on Thursday, February 12th. The shares were acquired at an average price of $24.85 per share, with a total value of $390,145.00. Following the completion of the acquisition, the director directly owned 15,700 shares in the company, valued at $390,145. This represents a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired 202,845 shares of company stock valued at $3,747,185 over the last quarter. Company insiders own 16.50% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Quarry LP increased its stake in Zenas BioPharma by 34.5% in the third quarter. Quarry LP now owns 1,134 shares of the company’s stock valued at $25,000 after purchasing an additional 291 shares during the last quarter. Russell Investments Group Ltd. acquired a new stake in Zenas BioPharma in the 3rd quarter worth about $30,000. GF Fund Management CO. LTD. acquired a new stake in Zenas BioPharma in the 4th quarter worth about $38,000. BNP Paribas Financial Markets grew its holdings in Zenas BioPharma by 120.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 3,146 shares of the company’s stock valued at $70,000 after buying an additional 1,716 shares during the period. Finally, CWM LLC increased its stake in shares of Zenas BioPharma by 48.3% during the 4th quarter. CWM LLC now owns 2,178 shares of the company’s stock valued at $79,000 after acquiring an additional 709 shares during the last quarter.

Key Zenas BioPharma News

Here are the key news stories impacting Zenas BioPharma this week:

• Positive Sentiment: Company says funding supports continued development of obexelimab — a key clinical program that underpins long‑term value, which helps stabilize investor confidence. Zenas BioPharma Funding Supports Obexelimab Plans
• Positive Sentiment: HC Wainwright reaffirmed a “buy” rating and kept a $44 price target, signaling strong upside from some sell‑side analysts and supporting bullish expectations. HC Wainwright Rating
• Neutral Sentiment: Citigroup trimmed its price target from $43 to $41 but maintained a “buy” rating — a modest downgrade to upside assumptions but not a change in overall endorsement. Citigroup Price Target Cut
• Neutral Sentiment: Morgan Stanley raised its target to $21 and kept an “equal weight”/Hold stance, reflecting a balanced near‑term view that recognizes pipeline potential but flags commercial and leverage uncertainties. Morgan Stanley / TipRanks Note
• Negative Sentiment: Quarterly results missed materially — Zenas reported EPS of ($4.54) vs. consensus of ($1.22). The magnitude of the miss increases short‑term downside risk and raises questions about near‑term cash burn and execution. Quarterly Earnings Press Release
• Negative Sentiment: New disclosure of an IPO‑related securities class action introduces additional financial and operational risk, which can pressure the stock while litigation remains unresolved. IPO-Related Class Action

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.